Esophageal SCC: chemoradiation most common US treatment

  • Verma V & al.
  • Cancer Med
  • 6 Nov 2018

  • curated by Kelli Whitlock Burton
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The majority of patients with nonmetastatic esophageal small cell carcinoma (ESCC) are treated with chemoradiotherapy (CRT), according to the largest study to date on the rare cancer.
  • Compared with chemotherapy alone, adding surgery or radiotherapy was associated with better OS.

Why this matters

  • National guidelines offer no consensus on the optimal treatment regimen for ESCC, and research on the best therapy has yielded conflicting results.

Study design

  • 323 patients with newly diagnosed, nonmetastatic ESCC from the National Cancer Database.
  • Funding: None disclosed.

Key results

  • 20% underwent surgical-based treatment, 65% CRT, and 15% chemotherapy alone.
  • No difference in OS between the surgery-based and CRT groups, but both had better OS than chemotherapy alone (P<.001>
  • Median OS for the surgery-based group was 21 (95% CI, 16-33) months vs 18 (95% CI, 15-23) months for CRT, and 10 (95% CI, 6-12) months for chemotherapy alone.
  • After multivariable analysis, receipt of additional local therapy (surgery or radiotherapy) was an independent predictor of better OS (P<.001 and older age increasing t n classification treatment at a community facility residence in an area with lower educational status were all independently associated poorer os for>

Limitations

  • Retrospective study.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit